Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations
Oncology reports, 2016.
EGFR and KRAS mutations are the two most common driver mutations in non-small cell lung cancer (NSCLC). Molecular target-based therapy using small molecules such as gefitinib has been used for inhibiting EGFR with good initial responses; however, drug resistance is common when using a mono-targeting strategy. At present, KRAS remains an u...More
Full Text (Upload PDF)
PPT (Upload PPT)